RxDoctor Payments Data

Madeline Brillhart, OD

Optometrist · Wilmington, NCNPI 1679212864

Payments from drug & device makers

$1,629in general payments, 2019–2025

Across 45 payments — averaging $36.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bausch & Lomb Americas Inc.$317
  • Sun Pharmaceutical Industries Inc.$197
  • Alcon$165
  • Genentech USA, Inc.$125
  • Amgen$124
  • Glaukos Corporation$123
  • plus $578 from 10 others

What the payments were for

  • Food & beverage$1,61299%
  • Education$161%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,629 in reported general payments places this provider in the 60th percentile of 1,326 optometrist providers in North Carolina.

See all optometrist providers in North Carolina

Medicare billing

Part B allowed, 2024
$99,074
Medicare patients
344
Services billed
1,453

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CombiganBrimonidine Tartrate/Timolol94$24,120
RocklatanNetarsudil Mesylat/Latanoprost48$22,157
LumiganBimatoprost34$12,118
Prednisolone Acetate248$7,911
VyzultaLatanoprostene Bunod25$7,608
RestasisCyclosporine12$6,575
Alphagan PBrimonidine Tartrate21$5,648
Travoprost25$4,717
Lotemax SmLoteprednol Etabonate17$4,208
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol51$3,711
SimbrinzaBrinzolamide/Brimonidine Tart14$2,992
Brimonidine Tartrate69$2,884
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat166$2,660
Latanoprost316$2,201
Fluorometholone26$2,049

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCombigan, Lumigan, Restasis, Alphagan P$87$48,460161 claims
Bausch & Lomb Americas Inc.Vyzulta$317$7,60825 claims
AlconSimbrinza$165$2,99214 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,326 optometrist providers in North Carolina.

Other optometrist in Wilmington

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →